FDA hold muddies Ipsen’s timeline for palovarotene in rare bone disease

A partial clinical hold on four studies of palovarotene that shaved $1.1 billion from Ipsen’s market cap on Friday could slow the biopharma’s timeline for a planned NDA to treat rare bone disease fibrodysplasia ossificans progressiva.

Spokesperson Christian Marcoux told BioCentury the company still intends to submit the palovarotene

Read the full 486 word article

User Sign In